Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-κ CAR-T
- Development stage
- Unknown
- Lead developer
- The Affiliated Hospital of Xuzhou Medical University
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
anti-κ CAR-T is an autologous chimeric antigen receptor (CAR) T-cell therapy targeting the immunoglobulin kappa (κ) light chain. Developed by the Affiliated Hospital of Xuzhou Medical University, this cell therapy is designed for the treatment of patients with relapsed or refractory multiple myeloma whose malignant plasma cells express the κ light chain. The treatment involves the genetic modification of a patient's own T cells to express a CAR that specifically recognizes and binds to the κ light chain on the surface of cancerous plasma cells. This targeted approach aims to selectively eliminate the malignant clone while sparing normal B cells and plasma cells that express the lambda (λ) light chain, potentially preserving some level of humoral immune function and reducing the breadth of B-cell aplasia compared to pan-B-cell targets. It is currently being evaluated in Phase 1 clinical trials in China.
- Other names
- anti-kappa CAR-Tkappa-directed CAR-Tanti-κ-CAR-T
02
Targets
Immunoglobulin light chain
Beyond the preview
Go deeper on anti-κ CAR-T.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-κ CAR-T.